Personalized mRNA Vaccine Sparks Long-Term Survival in Pancreatic Cancer

At the AACR meeting, researchers report a phase 1 trial of a patient-specific mRNA vaccine for pancreatic cancer, made from each patient's tumor material after surgery and used with immunotherapy and chemotherapy. Eight patients showed immune responses, and seven of these responders were alive up to six years post-surgery, with about 90% of responders remaining alive at follow-up. While promising, the findings come from a small early trial, and a global phase 2 study is now underway to assess broader efficacy.